Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the Medicines and Healthcare products Regulatory Agency plans to assess the long-term health implications of the mixture of Dicyclomine and Doxylamine in the previous pregnancy drug Debendox.

The Medicines and Healthcare products Regulatory Agency (MHRA) does not plan to assess the long-term health implications of the mixture of Dicyclomine and Doxylamine in the previous pregnancy drug Debendox. This medicine was withdrawn for commercial reasons from the market in the United Kingdom in the early 1980s.

MHRA remains alert to emerging evidence concerning the safety and efficacy of all medicines, taking action to protect the public when necessary. We encourage anyone to report side effect or adverse reactions to medicines they may have taken, however long ago, via the Yellow Card scheme.